This recombinant monoclonal antibody is developed as a research-grade biosimilar to reslizumab, targeting human interleukin-5 (IL-5), a key cytokine in eosinophil biology. IL-5 plays a central role in the differentiation, maturation, activation, and survival of eosinophils, making it critical in the pathophysiology of eosinophilic disorders. Elevated IL-5 levels are associated with severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and other allergic inflammatory conditions. By binding to IL-5, this antibody prevents interaction with the IL-5 receptor on eosinophils, thereby inhibiting eosinophil-mediated inflammatory responses.
Reslizumab is a humanized IgG4 kappa monoclonal antibody approved for treating severe eosinophilic asthma in adult patients. This biosimilar provides researchers with a valuable tool for investigating IL-5-mediated signaling pathways, eosinophil biology, and the mechanisms underlying allergic and inflammatory diseases. It supports studies exploring therapeutic interventions for eosinophilic disorders and enables detailed characterization of IL-5 function in various experimental models.
Email: support@cusabio.com
Distributors Worldwide